Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.52 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987637 | 0.84 | EGFR (0.73) | EGFRBRAFTNNI3KERBB2KDM4E | |
| SCHEMBL3324105 | 0.81 | EGFR (0.49) | EGFRBRAFTNNI3KCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL3320011 | 0.78 | EGFR (0.46) | EGFRMEN1KMT2A | |
| SCHEMBL6773322 | 0.78 | USP2 (0.43) | BRAFKDM4EMAPK1HTTCYP1A2 | |
| Hydrochloric Acid SCHEMBL6768789 | 0.77 | USP2 (0.43) | BRAFKDM4EMAPK1HTTCYP1A2 | |
| SCHEMBL30513 | 0.77 | EGFR (1.00) | EGFRBRAFERBB2KDM4EMAPK1 | |
| SCHEMBL29690398 | 0.77 | EGFR (1.00) | EGFRBRAFERBB2KDM4EMAPK1 | |
| SCHEMBL4586679 | 0.76 | EGFR (0.70) | EGFRERBB2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4594831 | 0.76 | EGFR (0.70) | EGFRBRAFERBB2CYP1A2CYP2D6 | |
| SCHEMBL2994916 | 0.73 | EGFR (0.38) | EGFRBRAFTNNI3KERBB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777032-B2 | N-4-[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine; use as type I receptor tyrosine kinase inhibitor; hyperproliferation diseases such as cancer; antiinflammatory agents | ARRAY BIOPHARMA INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7585975-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7501427-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ARRAY BIOPHARM, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ABL1, ERBB2, FLT3 | EGFR 8/4885BRAF 40/4885TNNI3K 233/4885 |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | EGFR 8/4885BRAF 40/4885TNNI3K 233/4885 |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | EGFR 8/4885BRAF 40/4885TNNI3K 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.